Teclistamab Improves Outcomes in Relapsed Multiple Myeloma

$Landscape infographic in University of Miami orange and green illustrating a treatment pathway for relapsed or refractory multiple myeloma, showing that about 70% of patients receiving teclistamab remained progression-free at 18 months compared with about 27% receiving standard therapy, with additional visual elements highlighting longer symptom control, slower disease worsening, and high remission rates.$

Teclistamab significantly improves survival and remission in relapsed multiple myeloma, advancing chemotherapy-free immunotherapy care.